Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sunday newspaper round-up: US-China, Aerospace, Pharma

(Sharecast News) - The US president said talks with China that were taking place in Geneva had achieved a "total reset" in the two countries' trade relations. Without elaborating, Donald Trump said that great progress had been made and that they wanted to see an opening up of China to American businesses. The negotiations were scheduled to continue on Sunday. - Guardian

The UK is near to reaching an agreement with Donald Trump that would grant an exemption from US tariffs to the country's £40bn aerospace sector. The business secretary also opened the door to an increase in quotas for British-made automobiles that can opt for a lower 10% US import tax. - The Sunday Times

As part of a wider trade deal, ministers are reviewing the controversial tax on medicines that pharma groups claim makes Britain "uninvestable". Companies including AstraZeneca and GSK do not yet know which tariffs, if any, they will have to pay. The US president has threatened to impose a 25% levy on UK drugs going to the US. - The Financial Mail on Sunday

The heads of companies paid billions of pounds by the government to house asylum seekers are set to see bumper increases in their pay. That is because asylum accommodation is expected to hit £15bn over a decade, three times what had been initially estimated. The companies are Mears, Serco and Clearsprings Ready Homes. According to the National Audit Office, the cost of asylum accommodation in 2024-25 alone hit £1.67bn, of which hotels accounted for 76%. - Financial Mail on Sunday

Share this article

Related Sharecast Articles

Thursday newspaper round-up: Höfner, Sotheby's, Christie's
(Sharecast News) - Ministers and senior MPs have warned that the UK's agreements with Donald Trump are "built on sand" after the Guardian established that the deal to avoid drug tariffs has no underlying text beyond limited headline terms. The "milestone" US-UK deal announced this month on pharmaceuticals, which will mean the NHS pays more for medicines in exchange for a promise of zero tariffs on the industry, still lacks a legal footing beyond top lines contained in two government press releases. - Guardian
Wednesday newspaper round-up: Grangemouth ethylene plant, Warner Bros, ChatGPT
(Sharecast News) - Jim Ratcliffe's chemicals company Ineos has been granted £120m of government funding to help save the UK's last ethylene plant at Grangemouth, in a deal expected to protect more than 500 jobs. The investment in the Scottish plant was necessary to preserve a vital part of the country's chemicals infrastructure, the UK government said. The ethylene produced there was essential for medical-grade plastics production, water treatment and in aerospace and car-building, it added. - Guardian
Tuesday newspaper round-up: Nissan, Morrisons, Ford
(Sharecast News) - Nissan has started the production of its latest electric car in Sunderland, a crucial step in the UK automotive industry's transition away from petrol and diesel. The Japanese manufacturer will launch the third generation of the Leaf on Tuesday, which was the first mass-market battery electric car to be built in the UK. Nissan has made 282,704 Leaf models at the north-east England plant so far. - Guardian
Monday newspaper round-up: Cryptocurrencies, jobs downturn, Cycle Pharma
(Sharecast News) - Cryptocurrencies will be regulated in a similar way to other financial products under legislation coming into force in 2027. The Treasury is drawing up rules that will require crypto companies to meet a set of standards overseen by the Financial Conduct Authority (FCA). Ministers have sought to overhaul the crypto market, which has ballooned in popularity as a way of investing money and making payments. Cryptocurrencies have not been subject to the same regulation as traditional financial products such as stocks and shares, which means that in many cases consumers do not enjoy the same level of protection. - Guardian

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.